A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.

The pill version of Novo Nordisk’s blockbuster Wegovy showed what was possible when drug chemists turned peptides into oral molecules. Now investors have found their

Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.

Denali’s Avlayah is the first drug for neurological complications associated Hunter syndrome to be approved in the US.

Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned an EU filing for its Alzheimer’s therapy.